$3.87
5.03% today
Nasdaq, Sep 04, 09:18 pm CET
ISIN
US92915B1061
Symbol
VYGR

Voyager Therapeutics, Inc. Stock price

$3.68
+0.47 14.64% 1M
-0.23 5.88% 6M
-1.99 35.10% YTD
-2.57 41.12% 1Y
-2.94 44.41% 3Y
-7.41 66.82% 5Y
-14.07 79.27% 10Y
-14.07 79.27% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.10 2.79%
ISIN
US92915B1061
Symbol
VYGR
Industry

Key metrics

Basic
Market capitalization
$204.1m
Enterprise Value
$-11.5m
Net debt
positive
Cash
$215.6m
Shares outstanding
55.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.8 | 6.7
EV/Sales
negative | negative
EV/FCF
0.1
P/B
0.8
Financial Health
Equity Ratio
76.3%
Return on Equity
-21.7%
ROCE
-44.1%
ROIC
-147.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$42.6m | $30.7m
EBITDA
$-119.2m | $-126.5m
EBIT
$-123.4m | $-139.0m
Net Income
$-107.9m | $-119.6m
Free Cash Flow
$-115.8m
Growth (TTM | estimate)
Revenue
-70.4% | -61.7%
EBITDA
-12,261.2% | -66.9%
EBIT
-3,109.3% | -72.7%
Net Income
-1,296.6% | -84.0%
Free Cash Flow
-420.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-279.9% | -412.2%
EBIT
-289.8%
Net
-253.5% | -389.7%
Free Cash Flow
-272.0%
More
EPS
$-1.9
FCF per Share
$-2.1
Short interest
6.4%
Employees
172
Rev per Employee
$470.0k
Show more

Is Voyager Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Voyager Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Voyager Therapeutics, Inc. forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Voyager Therapeutics, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Voyager Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
43 43
70% 70%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
0% 0%
88%
- Research and Development Expense 129 129
17% 17%
302%
-119 -119
12,261% 12,261%
-280%
- Depreciation and Amortization 4.22 4.22
13% 13%
10%
EBIT (Operating Income) EBIT -123 -123
3,109% 3,109%
-290%
Net Profit -108 -108
1,297% 1,297%
-253%

In millions USD.

Don't miss a Thing! We will send you all news about Voyager Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Voyager Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
2 days ago
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Citi's Biopharma Back to School Conference September 2, 2025 4:00 PM EDT Company Participants Alfred Sandrock - President, CEO & Director Todd Carter - Chief Scientific Officer Nathan Jorgensen - CFO, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation...
Neutral
GlobeNewsWire
9 days ago
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
29 days ago
- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise - - 11 partnered programs with potential for $2.6B in development-stage milestone payments - LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnolo...
More Voyager Therapeutics, Inc. News

Company Profile

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alfred Sandrock
Employees 172
Founded 2013
Website www.voyagertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today